Ambiguity On Diagnostic Regs Has Led To Tough Choices, Says CEO
This article was originally published in The Gray Sheet
Executive Summary
In the current regulatory environment for genetic tests, a manufacturer's best business plan may dictate an opposite path to market than its concerns about patient safety, says Tm Bioscience CEO Greg Hines
You may also be interested in...
FDA Draft Guidances Assert Oversight Over Multiplex Tests
CDRH is asserting its oversight authority in the development and use of high-tech tests that may fall through the cracks of current premarket practices via the release of two draft guidances Sept. 7
AdvaMed Reworks ASR Language In Hopes Of Influencing New FDA Guidance
AdvaMed currently is gathering information, including legal opinions, on how current analyte specific reagent regulations could be altered
FDA Clears Tm Bioscience Cystic Fibrosis Gene Test Via De Novo
FDA's de novo clearance of Tm Bioscience's Tag-It cystic fibrosis test kit paves the way for other CFTR gene mutation detection assays to be categorized as Class II